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Background: The incidence of Alzheimer’s disease, particularly in developing countries, is expected to increase
exponentially as the population ages. Continuing research in this area is essential in order to better understand this
disease and develop strategies for treatment and prevention. Genome-wide association studies have identified
several loci as genetic risk factors of AD aside from apolipoprotein E such as bridging integrator (BIN1), clusterin
(CLU), ATP-binding cassette sub-family A member 7 (ABCA7), complement receptor 1 (CR1) and phosphatidylinositol
binding clathrin assembly protein (PICALM). However genetic research in developing countries is often limited by
lack of funding and expertise. This study therefore developed and validated a simple, cost effective polymerase
chain reaction based technique to determine these single nucleotide polymorphisms.
Methods: An allele-specific PCR method was developed to detect single nucleotide polymorphisms of BIN1
rs744373, CLU rs11136000, ABCA7 rs3764650, CR1 rs3818361 and PICALM rs3851179 in human DNA samples. Allele-
specific primers were designed by using appropriate software to permit the PCR amplification only if the nucleotide
at the 3’-end of the primer complemented the base at the wild-type or variant-type DNA sample. The primers were
then searched for uniqueness using the Basic Local Alignment Search Tool search engine.
Results: The assay was tested on a hundred samples and accurately detected the homozygous wild-type,
homozygous variant-type and heterozygous of each SNP. Validation was by direct DNA sequencing.
Conclusion: This method will enable researchers to carry out genetic polymorphism studies for genetic risk factors
associated with late-onset Alzheimer’s disease (BIN1, CLU, ABCA7, CR1 and PICALM) without the use of expensive
instrumentation and reagents.
Keywords: Alzheimer’s disease, Single nucleotide polymorphism, Apolipoprotein E, Bridging integrator, Clusterin,
ATP-binding cassette sub-family A member 7, Complement receptor 1, Phosphatidylinositol binding clathrin
assembly protein, Allele-specific polymerase chain reactionBackground
Alzheimer’s disease (AD) is the most common cause of
dementia in the older population. The incidence and
prevalence of dementia is projected to increase exponen-
tially as the worldwide population ages. The estimated
number of people living with dementia worldwide in
2009 was approximately 34.4 million. The total societal* Correspondence: nuzoif@yahoo.com
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reproduction in any medium, provided the orcost of dementia worldwide in that year was estimated
to be US$422 billion [1]. More than 90% of all AD cases
are late-onset AD (LOAD), the AD subtype in which
symptoms appear after the age of 65 years [2]. Many
studies have demonstrated associations between LOAD
and genetic, lifestyle and environmental factors. Genetic
factors, however, are likely to play a crucial role [3]. The
strongest known genetic risk factor for LOAD is the ε4
allele of the APOE gene. A number of studies have iden-
tified APOE ε4 as a genetic susceptibility factor for AD
in different ethnic populations [4]. However, the impactLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and sensitivity of the genotype is only 68 and 65 percent re-
spectively [5]. As such, other genetic risk markers are likely
to play an important role in the development of LOAD.
The Alzgene database (www.alzgene.org) is a web-based
overview of collective data, systematic meta-analyses, and
regularly updated genetic association studies published in
the field of AD research. A number of SNPs from different
genes have been linked to AD through candidate gene
association and genome-wide association (GWA) studies
which have incorporated new high throughput and rapid
scanning genotyping technologies not readily available in
developing countries. The most common genes associated
with LOAD in this database on the Human Genome
Epidemiology Network (HuGENET) interim guidelines
for the assessment of genetic association studies (updated
18th April 2011) include APOE rs429358 and rs7412,
BIN1 rs744373, CLU rs11136000, ABCA7 rs3764650, CR1
rs3818361, PICALM rs3851179, MS4A6A rs610932, CD33
rs3865444, MS4A4E rs670139, and CD2AP rs9349407 [6].
Allele-specific polymerase chain reaction (AS-PCR),
also known as amplification refractory mutation system
(ARMS) or PCR amplification of specific alleles (PASA)
is a PCR-based method which can be employed to detect
the known SNPs [7]. The concept of AS-PCR was
initiated by Newton et al. [8], approximately six years
after PCR was invented. In this approach, the specific
primers are designed to permit amplification by DNA
polymerase only if the nucleotide at the 3’-end of the
primer perfectly complements the base at the variant or
wild-type sequences. After the PCR and electrophoresis,
the patterns of specific PCR products permit the differ-
entiation of the SNPs. Several innovative approaches
have been employed to detect the presence of specific
PCR product. Some are based on probe hybridization
which requires specific labelled probes [9] and melting
curve analysis [10] which requires nucleic acid stains.
AS-PCR has been utilized widely in many areas of study
such as pharmacogenetics [11], genetic disorders [12,13],
microbiology [14] and others.
This concept in determining SNP is relatively cheaper
than other available methods. Primer design and well-
optimized PCR methodology are the crucial aspects in
creating a working AS-PCR-based genotyping system.
Once the optimized protocol has been achieved, the
execution of AS-PCR is relatively simple, analogous to the
conventional PCR. The AS-PCR for APOE genotyping
was developed and utilized to differentiate the ε2/ε3/ε4
genotype in 1991 [15]. An improved method was
described in 1999 [16]. This study was therefore carried
out to develop, validate and utilize an AS-PCR method
to determine SNPs in the next five most common genes
from the Alzgene database (BIN1, CLU, ABCA7, CR1
and PICALM).Methods
Ethics approval
The study was conducted with the approval of the
Research Ethics Committee of Universiti Teknologi
MARA (UiTM) and the Medical Ethics Committee of the
University of Malaya Medical Centre (UMMC), which
adheres to the Declaration of Helsinki.DNA samples
Subjects were recruited from the memory and general
geriatric outpatient clinics of UMMC, Kuala Lumpur,
Malaysia from July of 2011 to June of 2012. 5 mls of
blood was collected from each subject after an informed
consent was obtained from the subject or his/her guard-
ian. Genomic DNA was extracted from the whole blood
using a QIAamp DNA Blood Mini Kit (Qiagen, USA)
according to the manufacturer’s instructions.Genotyping test
The genotyping method used to detect the selected
SNPs variants was developed using AS-PCR. Primers
were designed with the aid of Oligo Explorer 1.4 soft-
ware and searched for uniqueness using the NCBI
BLASTW search engine [17]. PCR was carried out using
a thermal cycler (Eppendorf Mastercycler Gradient;
Eppendorf, Hamburg, Germany). The final volume of all
PCR protocols was 25 μL.First round PCR
The first round PCR comprised of 1X GoTaqW Green
Master Mix (Promega Corp., WI, USA), 0.2 μM of
forward common (Fc) and reverse common (Rc) primer
of each gene, and approximately 50 ng of genomic DNA
for the amplification of each gene. 1% of dimethyl
sulphoxide (DMSO) was added only for the amplification
of ABCA7. After the amplification, 2 μL of a 1:50 dilution
of the first round PCR mixture was used in the second
round PCR amplification (AS-PCR) using Fc, Rc, forward
allele-specific (Fas) and reverse allele-specific primer
(Ras). The concentration of primers in the second round
PCR are shown in Table 1. The PCR cycling for the first
and second round were the same.AS-PCR for BIN1 rs744373
The mixture of second round PCR comprised of 1X
GoTaqW Green Master Mix, 2 μL of diluted first round
PCR product, BIN1-Fc, BIN1-Rc, BIN1-Fas and BIN1-
Ras primer. The PCR cycling was performed with an
initial denaturation at 80C for 5 minutes, followed by
35 cycles of amplification; 94C for 1 min, 63C for
30 s and 72C for 46 s. The final extension was
performed at 72C for 5 min.
Table 1 Sequence of primers and the concentration for the genotyping of the polymorphism of BIN1, CLU, ABCA7, CR1
and PICALM
Gene SNP ID Primer name Sequence (5’-3’) Concentration of
primer in AS-PCR (μM)
BIN1 rs744373 BIN1-Fc AAG ACG GAG AGA GGA GGC AT 0.4
BIN1-Rc CCA TCT TCT TCT GCT CTC CCA G 0.1
BIN1-Fas-W CAT GGG CAG CCT CTG AGA 0.1
BIN1-Ras-V AGG CAG GTC TGA GGC C 0.1
CLU rs11136000 CLU-Fc CCT GGC TTA AAG AAT CCA CTC ATC 0.1
CLU-Rc CAG GGG ATT CCT TTG AGA TAG AGT 0.1
CLU-Fas-W GCA AGG GCC CGT TAG AGA A 0.1
CLU-Ras-V CAA AGC CAC ACC AGC TAT CAA AAC 0.1
ABCA7 rs3764650 ABCA7-Fc AAA ATT AGC CAG GCG ACT TGG 0.05
ABCA7-Rc TCA GTG TCA CGG AGT AGA TCC 0.05
ABCA7-Fas-W GCT GCG AAC TTT GCA CCT 0.05
ABCA7-Fas-V GCT GCG AAC TTT GCA CCG 0.05
CR1 rs3818361 CR1-Fc TGC TCC ATA ACC AGT AGT TGA A 0.1
CR1-Rc CAC TCA CCC TTC ATC GCA AA 0.1
CR1-Ras-W TGG GGC AAT TTC CTT TGC 0.4
CR1-Fas-V CCT CTG GTA AGC ATA AGA TAT AA 0.4
PICALM rs3851179 PICALM-Fc TCT ATT TTC TGC CTT ACT GTC 0.04
PICALM-Rc GCT GTT CAG TAA ATC TGA ATT TCT 0.04
PICALM-Ras-W CCA TAT AAT AGT TGT GAT AGA TAA C 0.3
PICALM-Fas-V CAA ACA ATA CAC ACT TCA GTA AAT A 0.04
The specific nucleotides at the 3’-end of primers were underlined.
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The mixture of second round PCR comprised of 1X
GoTaqW Green Master Mix, 2 μL of diluted first round
PCR product, CLU-Fc, CLU-Rc, CLU-Fas and CLU-Ras
primer. The PCR cycling for CLU rs11136000 is the
same as BIN1 rs744373.AS-PCR for ABCA7 rs3764650
The second round PCR required the use of two separate
tubes for the amplification of wild-type and variant-type
allele. The first tube containing the PCR mixture for the
wild-type amplification comprised of 1X GoTaqW Green
Master Mix, 2 μL of diluted first round PCR product,
1% of DMSO, ABCA7-Fc, ABCA7-Rc and ABCA7-
Fas-W primer. The PCR mixture for the variant-type
amplification comprised similar elements as in the first
tube except for the ABCA7-Fas-W primer, which was
replaced with the ABCA7-Fas-V primer. The PCR
cycling was performed with an initial denaturation at
80C for 5 minutes, followed by 35 cycles of amplification;
94C for 1 min, 62C for 30 s and 72C for 51 s. The final
extension was performed at 72C for 5 min.AS-PCR for CR1 rs3818361
The second round PCR required the use of two separate
tubes for the amplification of wild-type and variant-type
allele. The first tube containing the PCR mixture for the
wild-type amplification comprised of 1X GoTaqW Green
Master Mix, 2 μL of diluted first round PCR product,
CR1-Fc, CR1-Rc and CR1-Ras-W primer. The PCR mix-
ture for the variant-type amplification comprised similar
elements as in the first tube except for the CR1-Ras-W pri-
mer, which was replaced with the CR1-Fas-V primer. The
PCR cycling was performed with an initial denaturation at
80C for 5 minutes, followed by 35 cycles of amplification;
94C for 1 min, 60C for 30 s and 72C for 40 s. The final
extension was performed at 72C for 5 min.AS-PCR for PICALM rs3851179
The second round PCR also required the use of two separ-
ate tubes for the amplification of wild-type and variant-type
allele. The first tube containing the PCR mixture for the
wild-type amplification comprised of 1X GoTaqW Green
Master Mix, 2 μL of diluted first round PCR product,
PICALM-Fc, PICALM-Rc and PICALM-Ras-W primer.
Figure 1 The electrophoresis profiles for some of the successful amplifications. BIN1 rs744373 (A), CLU rs11136000 (B), ABCA7 rs3764650 (C),
CR1 rs3818361 (D) and PICALM rs3851179 (E). W = lane for wild-type amplification, V = lane for variant-type amplification.
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Table 2 Different size of amplicons originated from different SNPs and genotypes
Gene Genotype Assay Interacted primers Size of
amplicons (bp)Forward Reverse












TT CLU-Fc CLU-Rc 685
CLU-Fc CLU-Ras-V 308
ABCA7 TT Wild type ABCA7-Fc ABCA7-Rc 846
ABCA7-Fas-W 369
Variant type ABCA7-Fc 846
TG Wild type ABCA7-Fc 846
ABCA7-Fas-W 369
Variant type ABCA7-Fc 846
ABCA7-Fas-V 369
GG Wild type ABCA7-Fc 846
Variant type ABCA7-Fc 846
ABCA7-Fas-V 369
CR1 GG Wild type CR1-Fc CR1-Rc 664
CR1-Ras-W 256
Variant type CR1-Rc 664
GA Wild type CR1-Rc 664
CR1-Ras-W 256
Variant type CR1-Rc 664
CR1-Fas-V 448
AA Wild type CR1-Fc 664
Variant type CR1-Fc 664
CR1-Fas-V 448
PICALM GG Wild type PICALM-Fc PICALM-Rc 718
PICALM-Ras-W 286
Variant type PICALM-Rc 718
GA Wild type PICALM-Rc 718
PICALM-Ras-W 286
Variant type PICALM-Rc 718
PICALM-Fas-V 481
AA Wild type PICALM-Fc 718
Variant type PICALM-Fc 718
PICALM-Fas-V 481
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comprised similar elements as in the first tube except for
the PICALM-Ras-W primer, which was replaced with the
PICALM-Fas-V primer. The PCR cycling was performed
with an initial denaturation at 80C for 5 minutes, followed
by 35 cycles of amplification; 94C for 1 min, 57C for 30 s
and 72C for 43 s. The final extension was performed at
72C for 5 min.
Agarose gel electrophoresis
After the amplification, electrophoresis was performed
at 100 V for 70 min in 1X tris-acetate-EDTA buffer on
1.5% agarose gel stained with ethidium bromide (0.5 μg/
μL). The amplified PCR products were visualized under
UV light.
Validation and accuracy of method
The method was validated by direct DNA sequencing
(First BASE Laboratory Sdn Bhd, Malaysia) using
BigDyeW Terminator v3.1 cycle sequencing kit chemistry
(Applied Biosystems). The accuracy of this AS-PCR was
verified by internal positive, external positive and exter-
nal negative control in all PCR runs.
Results
One hundred subjects were recruited for the study
(mean age, 76.78 ± 6.1 years; range, 65–94 years, 61%
female). Samples were genotyped for BIN1 rs744373,
CLU rs11136000, ABCA7 rs3764650, CR1 rs3818361
and PICALM rs3851179. The amplification and analysis
of each SNP was performed successfully as shown in
Figure 1. The presence of PCR bands with different sizes
in the agarose gel indicated the genotype of the samples.
Each reaction in different SNPs and genotypes are
shown in detail in Table 2. The PCR amplifications,
fragment size and accession number of DNA sequences
are illustrated in Figure 2 [GenBank: NT_022135.16,
NT_167187.1, NT_011255.14, NG_007481.1, and
NT_167190.1]. The results that were obtained from
the developed AS-PCR method were all consistent with
genotype data obtained using a direct DNA sequencing
technique.
Discussion
Two common primers (Fc and Rc) were designed to
flank and amplify the sequence containing the SNP. The
PCR products obtained from this amplification are non-
allele-specific amplicons as they are amplified constantly
for any genotype sample. In the first round PCR, these
amplicons can be used in the direct DNA sequencing
method for AS-PCR validation purposes. In the second
round PCR, these amplicons act as an internal positive con-
trol. Another pair of allele-specific primers (Fas and Ras)
were designed to amplify allele-specific amplicons whichwere shorter fragments compared to the non-allele-specific
amplicons (Figure 2). The nucleotide at the 3’-end of
each allele-specific primer perfectly matched the SNP
site. Fas-W or Ras-W and Fas-V or Ras-V primer were
complementary to the wild-type and variant-type genotype
sample respectively (Table 1).
The PCR was optimized by adjusting the concentration
of each primer. The optimum annealing temperatures
were determined using a gradient PCR. Under optimized
PCR components and conditions, the patterns of PCR
band that form after agarose gel electrophoresis allows the
differentiation of the SNPs in order to determine whether
the genotype was homozygous wild type, heterozygous or
homozygous variant. The inclusion of an external negative
control, a reaction containing all PCR components except
the DNA sample was to confirm the absence of contamin-
ation and false positive results. The inclusion of an external
positive control comprising the sequenced samples of each
genotype was to observe the efficiency of the assay and false
negative results. The genotyping test was further enhanced
by the addition of a common PCR fragment acting as an
internal positive control to guard against amplification
failures and increase the specificity of the method.
The protocol for ABCA7 genotyping required the use
of DMSO as the DNA region of interest had a high GC
content. Amplification of GC-rich regions of template is
difficult due to the formation of secondary intramolecular
structures as each GC pair is bound by three hydrogen
bonds. DMSO has been reported to improve the amplifi-
cation by interfering the self-complementarity of the DNA
template and primers [18]. As such, in order to amplify
this region which has 846 bp and 65.6% of GC content, a
satisfactory yield of specific PCR products was obtained by
including 1% of DMSO.
There are several methods that can be used to
detect SNPs such as PCR restriction fragment length
polymorphism (PCR-RFLP), high resolution melting
(HRM), pyrosequencing and probe hybridization based
techniques. PCR-RFLP has some disadvantages such as the
necessity of an incubation period for enzymatic digestion
by restriction endonuclease to separate the restriction
fragments [19]. The other methods mentioned above are
faster and easier to determine SNPs [20,21] but these
methods are expensive because they require the use of high
technology instrumentations and costly reagents.
The AS-PCR method developed in this study only
requires basic equipment such as a conventional thermal
cycler and a gel documentation system which are available
in most genetic laboratories. It is cost–effective as it does
not use fluorescent nucleic acid stains or hybridization
probes, whilst retaining test sensitivity and specificity by
the inclusion of positive and negative controls. This makes
it suitable to be used in studies where lack of funding,
equipment or expertise may be a factor.
Figure 2 Illustrations of PCR amplification and size of fragments. The common primers (A) flank and amplify the non-specific-allele
amplicons while the allele-specific primers (B) amplify the specific-allele amplicons to allow the differentiation of the genotypes. The DNA
sequences were retrieved from GenBank (National Center for Biotechnology) using accession numbers (C). The non-specific-allele amplicons act
as internal positive control (E). dsDNA = double-stranded DNA, Wt = wild-type, Vt = variant-type.
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The use of this method will therefore enable researchers to
carry out genetic polymorphism studies for genetic risk
markers associated with LOAD (BIN1, CLU, ABCA7, CR1
and PICALM) without the use of expensive instrumenta-
tion and reagents.
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